MSH2 and colorectal cancer: Some investigators have compared the cancer risk for carriers of an intragenic MSH2 mutation, a combined EPCAM-MSH2 deletion, and a deletion of the 3′ end of EPCAM. The colorectal cancer risk of EPCAM mutation carriers, as reflected by the mean age at diagnosis and the cumulative risk by age 70 years, was similar to that of EPCAM-MSH2 or MSH2 mutation carriers.